The role of gut microbiota in cancer treatment: friend or foe?
Wing Yin Cheng, Chun-Ying Wu, Jun Yu

ABSTRACT
The gut microbiota has been implicated in cancer and shown to modulate anticancer drug efficacy. Altered gut microbiota is associated with resistance to chemotherapeutic drugs or immune checkpoint inhibitors (ICIs), whereas supplementation of distinct bacterial species restores responses to the anticancer drugs. Accumulating evidence has revealed the potential of modulating the gut microbiota to enhance the efficacy of anticancer drugs. Regardless of the valuable findings by preclinical models and clinical data of patients with cancer, a more thorough understanding of the interactions of the microbiota with cancer therapy helps researchers identify novel strategy for cancer prevention, stratify patients for more effective treatment and reduce treatment complication. In this review, we discuss the scientific evidence on the role of gut microbiota in cancer treatment, and highlight the latest knowledge and technologies leveraged to target specific bacteria that contribute to tumourigenesis. First, we provide an overview of the role of the gut microbiota in cancer, establishing the links between bacteria, inflammation and cancer treatment. Second, we highlight the mechanisms used by distinct bacterial species to modulate cancer growth, immune responses, as well as the efficacy of chemotherapeutic drugs and ICIs. Third, we demonstrate various approaches to modulate the gut microbiota and their potential in translational research. Finally, we discuss the limitations of current microbiome research in the context of cancer treatment, ongoing efforts to overcome these challenges and future perspectives.

INTRODUCTION
The gut microbiota has emerged as a critical player in the maintenance of human health, influencing not only the GI tract but also distal organs such as the brain, liver and pancreas. As such, dysbiosis, which refers to compositional and functional alterations of the gut microbiome, contributes to the development of various pathological conditions, including obesity, diabetes, neurodegenerative diseases and cancers. Notably, bacterial infection can induce cancer. The colonisation of Helicobacter pylori causes persistent inflammation and leads to gastritis, driving gastric malignancy in a portion of infected individuals. Further analysis revealed that H. pylori promotes tumourigenesis via the activation of β-catenin signalling pathway. Conversely, eradication of H. pylori decreases the risk of gastric cancer in infected individuals, supporting its role in early stages of gastric carcinogenesis. Likewise, colorectal cancer (CRC), the development of cancer from the colon, is associated with specific bacteria. Recently, analysis of faecal metagenomic samples from patients with CRC identified CRC-enriched bacteria, including Bacteroides fragilis, Fusobacterium nucleatum, Porphyromonas asaccharolytica, Parvimonas micra, Prevotella intermedia, Alistipes finegoldii and Thermaeurabovirbio acidaminovorans, which may potentially serve as diagnostic bacterial markers across populations. The correlation of CRC-enriched bacteria with various pathways, such as lipopolysaccharide and energy biosynthesis, protein and mucin catabolism, and carbohydrate degradation, provides insights into their functional capacity in CRC. Moreover, compelling evidence suggests that microbial shifts are highly distinct across tumour stages. Two patterns of species elevation have been reported: the first consisted of a continuous increase from early stages onwards, while the other showed elevation only in early stages. The shifts in the microbiome and metabolome occurred at early stages. Two patterns of species elevation have been reported: the first consisted of a continuous increase from early stages onwards, while the other showed elevation only in early stages. The shifts in the microbiome and metabolome occurred at early stages. Two patterns of species elevation have been reported: the first consisted of a continuous increase from early stages onwards, while the other showed elevation only in early stages. The shifts in the microbiome and metabolome occurred at early stages.
Recent advances in basic science

identified by cross-cohort studies potentially enhance non-invasive microbial diagnostic tests, distinguishing CRC cases from normal individuals.

Series of in vitro and in vivo studies further highlight the mechanisms used by the gut microbiota to promote tumourigenesis. Gavage of faecal samples from patients with CRC promotes colon carcinogenesis in germ-free and conventional mice.23 Additional mouse models demonstrate that depleting the microbiota suppresses lung cancer development induced by Kras mutation and p53 loss.24 Bacteria have been reported to promote inflammation and cancer cell proliferation via cytokine production.11 22 Indeed, H. pylori and interleukin-22 (IL-22) induce matrix metalloproteinase-10 (MMP-10) in gastric epithelial cells via the extracellular signal-regulated kinase (ERK) pathway. MMP-10 not only induces inflammation through the production of chemokine ligand 16 (CXCL16) and recruitment of CD8+ T cells but also damages the gastric mucosa by inhibiting tight junction proteins.22 Besides animal models, gastric organoids show that the virulence factor CagA of H. pylori associates with c-Met receptor and cellular proliferation.23 Together, these studies illustrate the interaction of bacteria with different components of the tumour microenvironment to promote tumourigenesis.

Chronic inflammation plays an important role in carcinogenesis and colitis-susceptible IL-10-deficient mouse model identifies the gut microbiota as a target of inflammation that influences the progression of CRC.24 Colitis promotes tumourigenesis by altering the microbiota and inducing the expansion of bacteria with genotoxic capabilities.24 Enterotoxigenic Bacteroides fragilis (ETBF) has been reported to promote colon tumourigenesis by stimulating exaggerated immune responses via T helper 17 (Th17) cells in mouse CRC model.25 Gavaging mice that are prone to develop colon tumour with Peptostreptococcus anaerobius, another bacteria implicated in CRC, demonstrates that P. anaerobius not only interacts with toll-like receptor 2 (TLR2) and TLR4 on colon cells, but also promotes CRC via the modulation of various immune cell types, including myeloid-derived suppressor cells (MDSCs), tumour-associated macrophages (TAMs) and granulocytic tumour-associated neutrophils.26 27 Moreover, Fusobacterium nucleatum, one of the key drivers of CRC, has been shown to induce inflammatory and oncogenic responses via its virulence factors including FadA, Fap2 and LPS.28 29

In addition to its function in modulating inflammation, the microbiota influences the efficacy of cancer treatment. Preclinical data from a colon cancer mouse model identified Gammaproteobacteria as the key bacteria that metabolise gemcitabine, a chemotherapeutic drug, into its active form via cytidine deaminase.30 Human pancreatic ductal adenocarcinoma (PDAC) samples also contained elevated level of Gammaproteobacteria compared with normal pancreas. Culturing the bacteria from fresh human PDAC tumours with human colon carcinoma cell lines rendered the cell lines fully resistant to gemcitabine.31 The detection of Gammaproteobacteria may explain the gemcitabine resistance in PDAC patients and targeting these bacteria may sensitise tumour to gemcitabine treatment. Collectively, these findings describe the interactions between the gut microbiota and the host, which influence the process of tumourigenesis as well as the efficacy of cancer treatment. Alexander et al proposed a ‘TIMER’ mechanistic framework to illustrate how bacteria influence chemotherapy and the host in terms of translocation, immunomodulation, metabolism, enzymatic degradation, reduced diversity and ecological variation.32 33 The modulation of cancer immunotherapies by the microbiota has also been reported.33-37 In the following sections, we will explore the mechanisms used by distinct bacterial species to modulate the efficacy of chemotherapeutic drugs or immune checkpoint inhibitors (ICls). Next, we will describe the diverse approaches that enhance cancer treatment via altering the microbiota, and discuss the potential clinical application of such approaches.

BACTERIA THAT MAY IMPROVE CANCER THERAPY EFFICACY

Multiple studies demonstrate that the therapeutic efficacy was diminished in the absence of the gut microbiota, suggesting that, through different mechanisms, commensal microbes modulate the antitumour immune responses induced by the therapies. Cyclophosphamide (CTX), an approved chemotherapeutic drug, has been shown to alter the composition of intestinal microbiota in mice and promote the translocation of specific Gram-positive bacteria into secondary lymphoid organs, stimulating the production of ‘pathogenic’ Th17 cells, which share hallmarks of T helper 1 (Th1) cells and Th17 cells.38 39 Removal of the gut microbiota in germ-free mice or mice that have been treated with antibiotics leads to drug resistance to CTX.39 Although these approaches may be effective, they raise the concern that the bacterial species used for treatment may cause adverse effects.40 41 Therefore, it is important to identify and target specific bacterial species that promote tumourigenesis and cancer cell proliferation via cytokine production by immune cells including monocytes, macrophages and dendritic cells, and reduces tumour regression in mice receiving immunotherapy. These findings suggest that, through TLR4 activation, commensal microbes stimulate tumour-associated myeloid cells to produce inflammatory cytokines in response to immunotherapy and thereby improve patients’ outcome.36 Deeper mechanistic insights into the functions of commensal bacteria, as well as their interactions with the host, promote the design of microbial consortia that will improve the efficacy of cancer therapies.

BACTERIA THAT MAY PROMOTE CANCER GROWTH AND PROGRESSION

In contrast to the commensal microbes that can boost immune cells to fight cancer, subsets of pathogenic bacteria are associated with the development and progression of tumours. Using subcutaneous and liver metastases models of pancreatic cancer, colon cancer and melanoma, Sethi et al showed that antibiotics-mediated suppression of tumour growth involved adaptive immunity. This inhibitory effect was attenuated in Rag1-knockout mice that were deficient in mature T and B cells. Mechanistically, targeting the microbiota led to increased level of interferon-gamma (IFN-γ)-producing T cells and decreased level of IL-17a- and IL-10-producing T cells.40 Targeting the pathogenic bacteria may restore immune functions and augment the efficacy of cancer therapies. Fusobacterium nucleatum has been implicated in various types of cancer, including colorectal cancer.41 42-43 oesophageal
Recent advances in basic science

**Figure 1** Mechanisms used by gut bacteria to modulate anticancer drug efficacy. Bacterial species influence the efficacy of chemo drugs and immune checkpoint inhibitors via diverse mechanisms. Bacteria modulate the efficacy of 5-FU via bacterial vitamin B$_6$, B$_9$, and ribonucleotide metabolism. Inhibiting bacterial deoxynucleotide metabolism promotes the efficacy of 5-FU. *Barnesiella intestinihominis* and *Enterococcus hirae* play a critical role in the antitumour effect of another chemo drug, cyclophosphamide. Removing these bacterial species results in drug resistance to cyclophosphamide. Mechanistically, *E. hirae* translocates from the small intestine to secondary lymphoid organs and stimulates the production of pTh17 cells, whereas *B. intestinihominis* accumulates in the colon and promotes the infiltration of IFN-$\gamma$-producing $\gamma$-$\delta$ T cells in cancer lesions on treatment with cyclophosphamide. In addition, *Fusobacterium nucleatum* acts via TLR4 and MYD88, induces a selective loss of miR-18a* and miR-4802, activates autophagy and thereby promotes chemoresistance in patients. Furthermore, the antitumour effect of anti-CTLA-4 treatment depends on *Bacteroides* species. *Bacteroides fragilis* colonises the mucosal layer, induces T helper 1 immune responses in the lymph nodes and promotes the maturation of intratumorous dendritic cells, mediating the anticancer activity of the immune checkpoint inhibitor. 5-FU, 5-fluorouracil; IFN-$\gamma$, interferon-gamma; pTh17 cells, pathogenic T helper 17 cells.

Cancer, gastric cancer, head and neck squamous cell carcinoma, and pancreatic cancer. Studies with cell lines and mouse models have demonstrated that FadA adhesin on *F. nucleatum* binds to epithelial cadherin (E-cadherin), induces $\beta$-catenin signalling and modulates inflammatory and oncogenic responses to promote tumorigenesis. Abolishing the binding of *F. nucleatum* to E-cadherin by synthetic peptide suppresses CRC cell growth. In concordance with the preclinical data, patients with CRC display an elevated level of fadA in their colon tissues compared with normal individuals. Further examination of patients’ RNA revealed concomitant induction of Wnt7b and NFKB2 expression, suggesting a critical role of fadA in *F. nucleatum*-induced oncogenic and inflammatory responses. Another mechanism used by *F. nucleatum* to promote cancer growth is illustrated by studies that examined the functions of immune cells in the presence of *F. nucleatum*. These studies revealed that Fap2 protein of *F. nucleatum* inhibited natural killer (NK) cell cytotoxicity via its interaction with T cell immunoglobulin and ITIM domain (TIGIT), regulated the localisation of the bacteria to colorectal tumours and induced cell death in human lymphocytes. Besides its pro-tumourigenic effects, *F. nucleatum* contributes to chemoresistance and it was enriched in CRC patients with recurrence post-chemotherapy. Mechanistically, *F. nucleatum* acts via TLR4 and MYD88, induces a selective loss of miR-18a* and miR-4802, activates autophagy and thereby promotes chemoresistance in patients. Furthermore, the antitumour effect of anti-CTLA-4 treatment depends on *Bacteroides* species. *Bacteroides fragilis* colonises the mucosal layer, induces T helper 1 immune responses in the lymph nodes and promotes the maturation of intratumorous dendritic cells, mediating the anticancer activity of the immune checkpoint inhibitor. 5-FU, 5-fluorouracil; IFN-$\gamma$, interferon-gamma; pTh17 cells, pathogenic T helper 17 cells.


Gut: first published as 10.1136/gutjnl-2020-321153 on 5 August 2020. Downloaded from http://gut.bmj.com/ on September 28, 2021 by guest. Protected by copyright.
and lung cancer models revealed that vancomycin, an antibiotic targeting Gram-positive bacteria, potentiated the radiotherapy-induced antitumour response in mice by increasing CD8+ T cell infiltration and IFN-γ expression, whereas the supplementation of sodium butyrate, a key metabolite of Gram-positive bacteria, abolished the effect. The level of Gram-positive bacteria potentially influences patient’s response to radiotherapy.

**MICROBIAL BIOMARKERS FOR THERAPY EFFICACY**

The antitumour immune response of CTX has been shown to be enhanced by several bacterial species, such as *Lactobacillus johnsonii*, *Enterococcus hirae* and *Barnesiella intestinibominis*, identified by mouse models. Mechanistically, *E. hirae* translocates from the small intestine to secondary lymphoid organs and increases the intratumorous CD8/Treg ratio, whereas *B. intestinibominis* accumulates in the colon and promotes the infiltration of IFN-γ-producing γδ T cells in cancer lesions. Oral gavage with *E. hirae* restores the antitumour effect of CTX, which is otherwise ablated by antibiotics treatment. Additional mouse model identified nucleotide-binding oligomerisation domain-containing protein 2 as an inhibitor for the activity of *E. hirae* and *B. intestinibominis*.22

Similarly, the antitumour effect of anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) treatment depends on distinct *Bacteroides* species. Germ-free and antibiotics-treated mice do not respond to anti-CTLA-4 treatment; however, gavaging these mice with *Bacteroides fragilis* induces Th1 immune responses in the lymph nodes and promotes the maturation of intratumorous dendritic cells, restoring their response to CTX blockade. Similar observation in patients reveals that the efficacy of CTLA-4 antibody is associated with T cell responses mediated by *B. fragilis* or *Bacteroides thetaiotaomicron*. In addition, *Bifidobacterium breve*, *Bifidobacterium longum* and several other species have been reported to augment dendritic cell function, and thereby induce CD8+ T cell priming and accumulation in the tumour microenvironment. The supplementation of these bacterial strains may enhance the therapeutic efficacy of ICIs in patients with cancer. Furthermore, bacteria have been shown to suppress melanoma growth by attenuating the unfolded protein response (UPR) signalling pathway and mediating antitumour immunity. Mice lacking the ubiquitin ligase RNF5 exhibit an altered gut microbiota that correlates with decreased expression of UPR but increased expression of inflammasome components. Transfer of 11 bacterial strains enriched in *Rnf5*−/− mice promotes antitumour immunity and represses melanoma growth in germ-free wild-type mice. In accordance with the mouse data, patients that respond to immune checkpoint therapy exhibit significantly reduced level of UPR components. Modulation of selective bacterial species may enhance cancer immunotherapy and improve the outcomes of non-responders.

Complementing the preclinical mouse models, studies in patients highlight potential use of the gut microbiota in predicting treatment outcome. Analysing the faecal microbiota composition of metastatic melanoma (MM) patients receiving ipilimumab, an ICi targeting CTLA-4, revealed that patients with enriched level of *Faecalibacterium* and other Firmicutes were associated with not only longer survival but also increased occurrence of ipilimumab-induced colitis. Similar to CTLA-4, programmed cell death protein 1 (PD-1) is one of the inhibitory receptors which downregulate effector functions and suppress immune response. PD-1 blockade leads to significant tumour regression in a subset of patients with cancer. A metagenomic analysis of faecal samples from non–small cell lung cancer (NSCLC) and renal cell carcinoma (RCC) patients receiving anti-PD-1 treatment indicated that non-responders had reduced levels of *Akkermansia muciniphila*, which had been shown to promote the recruitment ofCCR9+CXCR3+CD4+ T lymphocytes to the tumour microenvironment via IL-12 pathway. On the other hand, two studies in patients with melanoma validated the presence of commensal microbes that potentiated the antitumour effects of PD-1 blockade in responders. Notably, responders display a higher alpha diversity and enriched levels of *Ruminococcaceae* and *Faecalibacterium*, which are associated with enhanced antigen presentation and T cell function in the tumour microenvironment. Taken together, a ratio of ‘beneficial’ bacteria to ‘non-beneficial’ bacteria is suggested to predict clinical response. Importantly, different cancer types, cancer treatments (chemotherapy vs immunotherapy), sample types (stool vs tissue) and approaches used to determine the microbial profile (16S vs metagenomic sequencing) may lead to biases and subsequently the identification of different species as beneficial bacteria. *Faecalibacterium prausnitzii*, for instance, plays a conflicting role in inflammation. *F. prausnitzii* has been associated with improved clinical response to immune checkpoint blockade, but it has also been shown to mitigate intestinal inflammation in the context of inflammatory bowel disease.

With its ability to produce short-chain fatty acids (SCFAs), which induce Treg cells and IL-10, *F. prausnitzii* would not be expected to promote antitumour immune responses. However, a recent study demonstrated that SCFAs enhanced memory potential of activated CD8+ T cells, suggesting that *F. prausnitzii* may potentiate antitumour immune response by promoting CD8+ T cells’ long-term survival as memory cells.

Likewise, pathogenic bacteria can also serve as diagnostic or prognostic markers. Metagenomic data of patients with cancer indicated that *F. nucleatum* was enriched in CRC tissues compared with normal tissues. Not only does the level of *F. nucleatum* increase with the degree of malignancy, but it also associates with metastasis. Further study of 309 subjects showed that complementing the faecal immunochromatographic test (FIT) with the detection of *F. nucleatum* improved diagnostic performance of FIT in colon cancer screening.

Additional analysis of human CRC cohorts unveils other features of *F. nucleatum*-associated CRC, including right-sided colon location, CpG island methylation phenotype-high (CIMP-H), high level of microsatellite instability (MSI-H) and poor prognosis. CRC with MSI-high status generally harbour numerous mutations and generate immunogenic peptides because of mismatch-repair deficiency. These alterations encourage antitumour immune response, leading to a more favourable prognosis and better response to immunotherapies. Considering these effects of MSI status, the Food and Drug Administration (FDA) approved the use of anti-PD1 antibodies, pembrolizumab and nivolumab, for CRC with high-MSI status. Interestingly, a study on 1041 patients with rectal and colon cancer demonstrated that the association of *F. nucleatum* with tumour-infiltrating lymphocytes (TIL) differed by tumour MSI status. The presence of *F. nucleatum* was negatively associated with TIL in MSI-high tumours, but positively associated with TIL in non-MSI-high tumours. The differential association of *F. nucleatum* with immune cells due to tumour MSI status suggests that *F. nucleatum* interacts with MSI status to mediate immune response within tumour. The *F. nucleatum*-induced changes in immune response influence cancer patients’ treatment outcome and overall survival. Despite these observations in patients with cancer that strongly suggest the use of *F. nucleatum* as a prognostic marker, the relationships between...
Analysis of the faecal samples of patients receiving radiotherapy suggested that patients with radiation enteropathy showed lower bacterial diversity but enrichment of specific microbial taxa, including *Clostridium IV* and *Roseburia*. FMT has been shown to alleviate radiation-induced GI toxicity and increase the survival rate of irradiated mice by improving GI tract function and epithelial integrity. Notably, FMT thickens the mucus layer of irradiated mice by upregulating the expression of Mac2, Glut1 (Slc2a1), Pgd1, intestinal trefoil factor (ITFF3/ITF1) and multidrug resistance protein 1 (MDR1). FMT also ameliorates radiation-induced bone marrow toxicity. Compared with FMT or bone marrow transplant alone, the combination treatment significantly increases the survival rate of irradiated mice, suggesting that FMT may serve as a radioprotector to improve prognosis of patients with cancer receiving radiotherapy.

In spite of its protective effect against cancer therapy-induced toxicities, FMT is associated with risks. Pathogens may be transmitted to the recipients via FMT. As such, robust microbiological screening is essential for abrogating the risk of transferring known pathogens, especially the ones carrying antimicrobial resistance. Nonetheless, it remains challenging to identify conditions for which FMT has true clinical potential. Limited data and knowledge on the role of FMT in cancer prevent the prediction of patient’s response to FMT. Further analysis of the microbial profile of donors and recipients, as well as the associated mechanistic insights, is crucial for effective FMT treatment in patients.

**BACTERIA DEPLETION BY ANTIBiotics OR OTHER MEANS**

Given their contribution to tumourigenesis, carcinogenic bacteria have been depleted by various means to prevent cancer or delay tumour growth. Among these pathogens, *H. pylori’s* role in gastric tumourigenesis is well-established. Eradication of *H. pylori* by a combination of amoxicillin and clarithromycin in patients with early gastric cancer is associated with lower rates of developing metachronous gastric cancer and improvements in the grade of glandular atrophy at the corpus. Conversely, an analysis of 125 441 cancer cases and 499 510 control cases indicated that antibiotic treatment positively correlated with cancer risk. Antibiotics have also been associated with reduced survival in patients with advanced renal cell carcinoma receiving anti-programmed cell death ligand-1 (PD-L1) monoclonal antibody (mAb) monotherapy, suggesting that the removal of commensals underlines the efficacy of ICIs.

The conventional use of antibiotics alters the commensal microbiota, leading to collateral damage to patients. Novel technologies, such as CRISPR-Cas9 system delivered by phage, targeting specific bacteria at the microbiome–cancer interface are needed to minimise perturbation to the commensal microbiota, and to ensure effective cancer treatment. Notably, administration of irinotecan-loaded dextran nanoparticles covalently linked to azide-modified phages that target *F. nucleatum* in the tumours augments the effect of chemotherapy against CRC. The phage treatment is restricted to GI tumours, reducing potential toxicities associated with therapy. Ongoing clinical trials have proven the utility of nanoparticles in drug delivery with increasing number of nanomedicines being approved for various indications.

Nanotechnologies can be used to target tumour-associated bacteria or to release anticancer drugs in a controlled manner, causing fewer side effects in patients. Given the implications of nanotechnologies for cancer prevention and treatment, efforts...
should be directed to evaluating toxicity, side effects and downstream mechanisms mediated by nanoparticles.

**BACTERIA COMPOSITIONAL MODULATION BY PROBIOTICS IN CANCER**

Numerous clinical trials have been conducted to investigate the effects of probiotics/prebiotics on cancer. Some trials reported an improved clinical outcome of patients receiving probiotics, whereas others failed to examine a significant effect induced by probiotics (online supplementary S table 1).

A prospective intervention study on patients with CRC revealed that the administration of *Lactobacillus acidophilus* NCFM and *Bifidobacterium lactis* Bl-04 altered patients’ microbial profile. The probiotics increased the abundance of butyrate-producing bacteria, such as *Faecalibacterium* and *Clostridiales* spp, while decreasing the abundance of CRC-associated genera, including *Fusobacterium* and *Peptostreptococcus*. In addition to altering the microbial profile, probiotics have been reported to inhibit cancer progression in animal models. Using a diethylaminoethanol (DEN) model of rat hepatocarcinogenesis, Zhang et al demonstrated that the administration of the probiotic mixture VSL#3 mitigated intestinal inflammation on DEN treatment, maintained the intestinal mucosa integrity and suppressed tumour growth. A subsequent study demonstrated that the probiotic mixture Prohep reduced the level of Th17 cells in the tumour, thereby inhibiting hepatocellular carcinoma (HCC) progression in a subcutaneous transplant mouse model. Clinical trials assessing the therapeutic potential of VSL#3 in patients with cirrhosis or non-alcoholic fatty liver disease suggested that probiotics improved the severity of the diseases that are strongly linked to the development of HCC.

Recently, a study by Riehl et al delineated the mechanism of *Lactobacillus rhamnosus* GG (LGG) radioprotection. Tumour-bearing mice were treated with phosphate buffered saline alone, irradiation alone, LGG alone or LGG followed by irradiation. The result demonstrated that LGG releases lipoteichoic acid (LTA), which binds to TLR2 on pericytial macrophages and promotes chemokine CXCL12. CXCL12 in turn binds to CXCR4 on cyclo-oxygenase-2 expressing mesenchymal stem cells, driving their migration to the pericytial region and producing prostaglandin E2 that protects epithelial stem cells from radiation-induced apoptosis. Yet, this mechanism remains to be validated in human.

In addition to radioprotection, probiotics may manipulate host inflammatory status, thereby influencing the efficacy of cancer therapy. Several clinical trials, however, deny the clinical benefits of probiotics in cancer treatment. Treating patients with head and neck cancer with a cocktail of *Lactobacillus* and *Bifidobacterium* strains after surgery did not improve the clinical outcome of patients. Patients receiving the probiotics and those receiving the placebo had similar rate of postoperative infection and displayed comparable level of inflammatory markers and diamine oxidase, an indicator of gut permeability. The conflicting results of clinical trials may be explained by interindividual variations in microbiome and host genome. Colonisation and function of probiotics are influenced by indigenous microbiota, gene-expression profile of the host and other exogenous factors. Due to these variations, it remains challenging to assess the clinical benefits of probiotics in patients with cancer. In addition, the majority of the clinical trials on probiotics shares limitations, such as small sample size, short duration of treatment and lack of follow-up to examine the long-term effect of probiotics on patients. Therefore, well-designed studies are critical for the evaluation of probiotic treatment in patients with cancer. Interestingly, a recent study investigated the effects of 11-strain probiotics or autologous faecal microbiome transplantation (aFMT) on post-antibiotic reconstitution of mouse and human microbiota. The result indicated that probiotics significantly delayed microbiome reconstitution, while aFMT induced a rapid and near-complete recovery within days of administration. On the basis of this finding, aFMT, instead of probiotics, may be used to reconstitute the microbiome in antibiotics-perturbed patients.

**ORGANOID PROVIDE DEEPER MECHANISTIC INSIGHTS INTO THE ROLE OF THE GUT MICROBIOTA IN CANCER**

Organoids cultured from pluripotent stem cells or tissues maintain many characteristics of their respective tissues, including histology and expression of markers. With these properties, organoids are adopted for disease modelling and drug screening. Organoids overcome drawbacks of current studies using cell lines or mouse models, including limited access to human samples and intrinsic differences between mouse models and human physiology. The addition of bacteria to organoid culture allows the study of host–bacteria interactions and offers a deeper mechanistic insight than two-dimensional culture.

A study confirmed the pro-tumourigenic effect of *H. pylori* via microinjection of the bacteria into human gastric organoids. The CagA protein of *H. pylori* binds to the c-Met receptor of organoid epithelial cells, phosphorylates c-Met and promotes epithelial cell proliferation. Moreover, human monocyte-derived dendritic cells (DCs) were cocultured with gastric organoids and subsequently exposed to *H. pylori*. The result showed that DCs migrated to and interacted with gastric epithelial organoids and their migration was enhanced by *H. pylori* infection. This coculture system recapitulated what happened in vivo during a bacterial infection. DCs are recruited to the gastric mucosa on *H. pylori* infection to promote phagocytosis of *H. pylori*. Furthermore, fusion of organoids and coculture of multiple organoids has recently been proposed to enhance the structural complexity and functional maturation of organoids. Clinically, patient-derived organoids may be used for predicting tumour’s sensitivity to various therapies.

**FUTURE PERSPECTIVES AND CONCLUSIONS**

With advances in sequencing technology and development of powerful computational tools, the research paradigm has shifted from association-based approach to mechanism-based approach. The mere presence or absences of certain bacterial species provides limited insight into the role of the gut microbiota in cancers. Indeed, unravelling causal links between bacteria and cancers, as well as the underlying mechanisms, has become the focus of intense research. Moreover, altered viromes and fungal microbiota have been implicated in CRC, suggesting that these microorganisms may interact with gut bacteria to modulate patients’ response to cancer treatment. The integrated analysis of the gut microbiome and its interactions with the host, anticancer drugs and other exogenous factors is essential for improving the outcomes of cancer patients (online supplementary S table 2).

Gnotobiotic animal models have been widely used to examine the colonisation of specific bacterial species in the gut and their biological functions in the context of cancer, and to provide the proof of principle needed to direct and interpret human studies. However, differences in physiology of the intestinal tract, dietary patterns and genetics suggested that the mouse...
Recent advances in basic science

Microbiota differs significantly from the human microbiota. Reproducibility of mouse microbiota studies and their conclusions are to be interpreted with caution, and the findings are to be validated extensively by large-scale, multicentre clinical trials. Collaborative efforts to elucidate the role of the gut microbiota in shaping responses to cancer therapy are evident in several ongoing trials that evaluate the effect of FMT in patients with cancer who are impervious to ICIs. The teams conducting these trials propose that non-responders lack beneficial bacteria that are critical for the antitumour effect of immunotherapy, and that transplanting these bacteria from responding patients to non-responders restore their response to ICIs (NCT04130763, NCT04116775, NCT03353402, NCT03341143). These trials, along with further validations, will determine if selective modulation of gut microbiota, either by FMT, probiotic treatment or other means, enables patients with cancer to overcome resistance to immune checkpoint therapy (figure 2).

Accumulating evidence has underscored the critical role of the gut microbiota in cancer therapies. Some bacterial species are essential for the antitumour effect of cancer treatment, whereas other species attenuate the efficacy of cancer drugs via diverse mechanisms. Given the relationships between host, gut microbiota and cancer treatments, research efforts have been directed to investigate the mechanisms used by bacteria to modulate patients’ response to treatment and their clinical outcomes. In this review, we explored the dynamic interactions between the host, the gut microbiota and various cancer treatments, including chemotherapies and immunotherapies. Regardless of the recent advances in the field of microbiome research, limitations of current research hamper the clinical applications of bacterial therapies. Of note, strong associations between distinct bacterial species and cancers have been established, but the underlying mechanisms remain elusive and need extensive validation via preclinical models and clinical trials. Nonetheless, recent findings supported the potential of microbial markers or enterotypes in cancer diagnosis and prognosis, the potential of phage therapies in targeted delivery of cancer drugs, and the potential of FMT or probiotics in remodelling the tumour microenvironment or in potentiating antitumour immunity. The role of the microbiota in cancer is context-dependent. Bacteria

---

Figure 2. Preclinical mouse models and sequencing data of patients with cancer are valuable tools in microbiome research that contribute to the development of novel therapeutics for patients with cancer. Preclinical mouse models are valuable tools to dissect the mechanisms of defined bacteria in the absence of microbes (germ-free mice) or in the presence of limited number of microbes (antibiotic treatment). However, limitations, such as selection bias, prevent these preclinical models from fully recapitulating the interactions between the gut microbiota and cancer cells in humans. The antibiotic treatment may select for resistant bacteria or promote fungal outgrowth, confounding the result of the experiment. Other factors, including the housing environment, the diet and the genetic background of the mice, also influence the microbial communities residing in the mice and their interaction with tumour cells or anticancer drugs. To complement these preclinical models, cancer patients’ sequencing data are examined in terms of the host genome, metabolome and immune profile before and after anticancer treatment. Together, the mouse models and meta-analysis of human sequencing data provide insights into the relationship between the gut microbiota and cancer treatment. Modulating the gut microbiota by selectively targeting cancer-associated bacteria with phages, by administering probiotics or by performing FMT, may reshape the tumour microenvironment and the host immune responses, thereby augmenting the efficacy of anticancer drugs and improving the outcome of cancer patients. FMT, faecal microbiota transplant.
interact with a plethora of host, as well as exogenous factors in patients with cancer and influence tumourigenesis via diverse mechanisms. Overall, a more comprehensive understanding of the functions of distinct bacteria in host physiology and in cancer treatment is critical to the development of personalised medicine that enhances patients’ response to cancer therapies by modulating the gut microbial composition and function.

Contributors WYC researched the data for the article, contributed substantially to the development of the manuscript. JY designed the content and rewrote the manuscript.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD Jun Yu http://orcid.org/0000-0001-5008-2153

REFERENCES
4 Foley KP, Zlitni S, Denou E, et al. Patient consent for publication
14 Foley KP, Zlitni S, Denou E, et al. Patient consent for publication
14 Foley KP, Zlitni S, Denou E, et al. Patient consent for publication
14 Foley KP, Zlitni S, Denou E, et al. Patient consent for publication
et al. 2020;1867–1876. doi:10.1136/gutjnl-2020-321153


Recent advances in basic science


